Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5Brain Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Meningeal Neoplasms 1Breast Cancer Metastatic 1

Interventions

Cyclophosphamide 3fludarabine 2Radiotherapy 2Interleukin-2 2tislelizumab 1pembrolizumab 1pazopanib 1patritumab deruxtecan 1palbociclib 1niraparib 1neotil 1lenvatinib 1atezolizumab 1Yoga 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Tiragolumab 1Surveys and Questionnaires 1Radiation 1Positron-Emission Tomography 1Nivolumab 1Magnetic Resonance Imaging 1Lacteol 1Ipilimumab 1High-Throughput Nucleotide Sequencing 1Fluorodeoxyglucose F18 1Data Collection 1Cryosurgery 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumor, Adult × patritumab deruxtecan × Clear all
NCT06383884 2025-12-15

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Samsung Medical Center

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡